Drugs / GSK2696273
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00598481 | Oct 2002 → Jul 2011 | immunodeficiency disease | Fondazione Telethon | Completed | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK2696273 | “GSK2696273 (autologous CD34+ cells transduced with retroviral vector that encodes for the human adenosine deaminase [ADA] enzyme) is a gamma-retroviral ex vivo gene therapy” PMID 28319446 ↗ Mar 2017 |
| Action | Restore | “partial to full correction of ADA expression” PMID 19652199 ↗ Aug 2009 |
| Target | ADA | “encodes for the human adenosine deaminase [ADA] enzyme” PMID 28319446 ↗ Mar 2017 |